Nuveen’s Takeda Pharmaceutical TAK Stock Holding History

Nuveen’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-74,190	Closed	-$1.05M	–	3413
2024 Q1	$1.05M	Buy	74,190 +3,390	+5%	+$49.3K	﹤0.01%	2683
2023 Q4	$1.01M	Buy	70,800 +69,868	+7,497%	+$991K	﹤0.01%	2732
2023 Q3	$14.4K	Buy	+932	New	+$14.4K	﹤0.01%	3180
2022 Q1	–	Sell	-583,493	Closed	-$7.95M	–	3422
2021 Q4	$7.95M	Sell	583,493 -1,320,181	-69%	-$18.5M	﹤0.01%	1826
2021 Q3	$31.2M	Sell	1,903,674 -31,391	-2%	-$527K	0.01%	964
2021 Q2	$32.6M	Buy	1,935,065 +247,697	+15%	+$4.22M	0.01%	1010
2021 Q1	$30.8M	Buy	1,687,368 +462,051	+38%	+$8.31M	0.01%	1015
2020 Q4	$22.3M	Buy	+1,225,317	New	+$21.5M	0.01%	1194
2020 Q1	–	Sell	-67,708	Closed	-$1.34M	–	3259
2019 Q4	$1.34M	Hold	67,708	–	–	﹤0.01%	2583
2019 Q3	$1.17M	Hold	67,708	–	–	﹤0.01%	2632
2019 Q2	$1.2M	Buy	+67,708	New	+$1.23M	﹤0.01%	2663

Other funds holding TAK

GAM

Groupama Asset Management Paris, France $6.85B AUM 43.37% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Nuveen's TAK Position: Q2 2024 in Review

Nuveen sold out of Takeda Pharmaceutical (TAK) in Q2 2024, closing a stake of 74,190 shares — an estimated $1.05M sold.

Nuveen first reported a position in TAK in Q2 2019 and held it in 11 quarters. The position peaked at $32.6M in Q2 2021. 283 funds tracked by Wall St. Rank hold TAK as of Q2 2024.

Nuveen reported no remaining Takeda Pharmaceutical position as of Q2 2024 after selling out during the quarter.
Nuveen sold 74,190 Takeda Pharmaceutical shares in Q2 2024, an estimated $1.05M.
Nuveen first reported a position in Takeda Pharmaceutical in Q2 2019 and held it in 11 quarters.
Nuveen's Takeda Pharmaceutical position peaked at $32.6M in Q2 2021.
283 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2024.

Based on Nuveen's 13F filing for Q2 2024, filed 9 Aug 2024.